- Home
- UAN vs DNTH Comparison
UAN vs DNTH Comparison
Compare UAN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAN
- DNTH
- Stock Information
- Founded
- UAN 2007
- DNTH 2015
- Country
- UAN United States
- DNTH United States
- Employees
- UAN N/A
- DNTH N/A
- Industry
- UAN Agricultural Chemicals
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- UAN Industrials
- DNTH Health Care
- Exchange
- UAN Nasdaq
- DNTH Nasdaq
- Market Cap
- UAN 793.5M
- DNTH 724.8M
- IPO Year
- UAN 2011
- DNTH N/A
- Fundamental
- Price
- UAN $80.00
- DNTH $23.67
- Analyst Decision
- UAN
- DNTH Strong Buy
- Analyst Count
- UAN 0
- DNTH 9
- Target Price
- UAN N/A
- DNTH $46.43
- AVG Volume (30 Days)
- UAN 24.0K
- DNTH 198.9K
- Earning Date
- UAN 02-18-2025
- DNTH 03-20-2025
- Dividend Yield
- UAN 8.48%
- DNTH N/A
- EPS Growth
- UAN N/A
- DNTH N/A
- EPS
- UAN 5.76
- DNTH N/A
- Revenue
- UAN $525,323,999.00
- DNTH $5,366,000.00
- Revenue This Year
- UAN N/A
- DNTH $100.14
- Revenue Next Year
- UAN N/A
- DNTH N/A
- P/E Ratio
- UAN $13.84
- DNTH N/A
- Revenue Growth
- UAN N/A
- DNTH 51.41
- 52 Week Low
- UAN $61.62
- DNTH $18.35
- 52 Week High
- UAN $88.94
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- UAN 52.22
- DNTH 53.31
- Support Level
- UAN $75.35
- DNTH $22.77
- Resistance Level
- UAN $82.78
- DNTH $25.46
- Average True Range (ATR)
- UAN 2.65
- DNTH 1.49
- MACD
- UAN -0.15
- DNTH 0.13
- Stochastic Oscillator
- UAN 62.58
- DNTH 57.18
About UAN CVR Partners LP Common Units representing Limited Partner Interests
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.